# GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/GHRS/gh-research-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: GHRS
Company: GH Research
Source: GH Research
Published: 2026-05-14 11:00 EST
Original Source URL: https://investor.ghres.com
## Summary

Phase 2b results in TRD published in  JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March

## Article Body
Phase 2b results in TRD published in  JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March
## Recent Company News
- 2026-06-04 11:00 EST — [GH Research Announces Publication of Phase 2a Postpartum Depression Results](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2a-postpartum-depression-results) — Source: GH Research
- 2026-05-14 11:00 EST — [GH Research Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/GHRS/gh-research-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: GH Research
- 2026-04-29 12:00 EST — [GH Research Announces Pricing of $117.5 Million Underwritten Offering](https://biopharmsignal.com/news/GHRS/gh-research-announces-pricing-of-117-5-million-underwritten-offering) — Source: GH Research
- 2026-04-20 13:00 EST — [GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness](https://biopharmsignal.com/news/GHRS/gh-research-welcomes-white-house-executive-order-to-accelerate-medical-treatments-for-serious-mental-illness) — Source: GH Research
- 2026-03-25 15:11 EST — [GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD](https://biopharmsignal.com/news/GHRS/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-gh001-in-jama-psychiatry-and-reports-new-finding-of-severity-independent-efficacy-in-trd) — Source: GH Research
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)